Articles

Training people with diabetes to teach other patients improves utilization of medications and results in lifestyle changes….

Type 2 diabetes patients with microvascular or macrovascular complications, or those taking certain monotherapies, are more likely to experience hypoglycemia and require outpatient hospital visits….

The perception that diet soft drinks are a benign alternative to highly sweetened beverages might be dangerously wrong….

In patients diagnosed with type 2 diabetes through screening in general practice, intensive multifactorial treatment improved cardiovascular risk factors, compared with usual care, new findings suggest, but those improvements were very small.…

Higher levels of vitamin D in the blood appear to be associated with a reduced risk for incident diabetes among people at high risk for the disease.…

Takeda Pharmaceuticals recently completed a Phase 2 study with its novel anti-diabetic agent TAK-875, which could help lead to more individualized patient care and diabetes management….

The vascular endothelial growth factor (VEGF) inhibitor ranibizumab (Lucentis) proves promising in treating diabetic macular edema….

We asked our readers to give us feedback into how much they knew about GLP-1 Analogs and a broad cross-section replied. Take a look at 5 of the questions and how your colleagues answered…. It appears that most of you knew that a large amount of GLP-1 production is lost …

In order to increase compliance and improve efficacy, there is an experimental long acting exenatide once monthly injectable suspension in the pipeline. This long acting formulation is currently in phase-2 trial and has showed promising results in controlling A1C in type 2 diabetes patients….

The investigational drug Lyxumia® (lixisenatide), a once daily GLP-1 agonist, is making progress as a newer drug in this increasingly crowded class of drugs.  Data from four studies of the GetGoal Phase III clinical program was presented at the ADA sessions….